Ibon
Ibon Calvo Echeveste, Aretxabaleta ES
Patent application number | Description | Published |
---|---|---|
20140145062 | FORMWORK STRUCTURAL MEMBER - A formwork structural member having at least one core made of a material that has a density between approximately 40 kg/m | 05-29-2014 |
Ibon Garitaonandia, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20100261178 | High Throughput Assays for Inhibitors and Activators of PAQR Receptors - The subject invention provides methods of screening compounds or ligands that interact with human and/or non-human PAQR receptors or fungal osmotin receptors. These methods utilize a colorimetric assay to ascertain whether a compound binds to and activates a PAQR receptor or the osmotin receptor. | 10-14-2010 |
Ibon Garitaonandia, Carlsbad, CA US
Patent application number | Description | Published |
---|---|---|
20140314721 | USE OF NEURAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject. | 10-23-2014 |
20150087541 | Derivation of Neural Stem Cells and Dopaminergic Neurons from Human Pluripotent Stem Cells - The present invention is based in part on a chemically defined method of generating neural stem cells (NSCs) and dopaminergic (DA) neurons from human pluripotent stem cells (hPSCs). The DA neurons of the invention can be derived from hPSCs and NSCs. The present invention also provides reagents and kits useful for the derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells. | 03-26-2015 |
Ibon Gochi Garcia, Algorta (vizcaya) ES
Patent application number | Description | Published |
---|---|---|
20130054800 | EFFICIENT DATA DELIVERY METHOD AND APPARATUS - A method of delivering data to user terminals connected to an Internet Protocol Connectivity Access Network, IP-CAN, wherein the IP-CAN implements a Policy and Charging Control, PCC, architecture. The method comprises caching data within an IP-CAN cache server upon a decision made by a Policy and Charging Rules Function, PCRF, of the PCC architecture. The cached data is then identified to a Policy and Charging Enforcement Function, PCEF, of the PCC architecture. At the PCEF, data requests made by user terminals are monitored and a determination made as to whether or not a request relates to cached data. If a request does relate to cached data, then that cached data is delivered from the IP-CAN cache server to the requesting user terminal. | 02-28-2013 |
20140211813 | UNOBTRUSIVE CONTENT COMPRESSION IN A TELECOMMUNICATIONS NETWORK - A telecommunications network policy enforcing point operable to route IP datagrams in a two-way communication between a first endpoint in a telecommunications network and a second endpoint in the telecommunications network and operable to compress, in accordance with a data compression policy, IP datagrams of a response transmitted by the second endpoint to the first endpoint. The response is of a layer 7 protocol that supports compression, a layer level being an Open Systems Interconnection, OSI, layer in an OSI Reference Model, and each IP datagram of the response comprises a sequence of bytes of data and a header defining a sequence number of the first byte of data in the IP datagram. | 07-31-2014 |
20140250218 | ADVANCED DETERMINATION, PROCESSING AND CONTROL IN COMMUNICATION NETWORKS - A method is carried out by at least one network node in a communication network. The method includes determining, from received packets, at least one characteristic of at least one end user device connected, through an end user communication terminal, to the communication network. The determining procedure includes inspecting at least one of (a) layer n control information of the received packets, wherein n is an integer one of equal to and larger than 3, and (b) the received packets' payload encapsulated by layer 7 control information. The layer level is an OSI layer in an OSI reference model. The invention also relates to network nodes and computer programs. | 09-04-2014 |
Ibon Gochi Garcia, Vizcaya ES
Patent application number | Description | Published |
---|---|---|
20140016513 | METHODS AND APPARATUS FOR DETERMINING A LANGUAGE - According to a first aspect of the present invention there is provided a method of operating a telecommunications network to determine a language to be used for a message that is to be sent to a terminal of a user of the network. The method comprises the steps of inspecting packets sent over the network to and/or from a terminal used by the user in order to identify one or more languages specified within application layer protocol information contained in the packets; and selecting an identified language as the language that is to be used for the message. | 01-16-2014 |
Ibon Gutierro Aduriz, Granada ES
Patent application number | Description | Published |
---|---|---|
20100316722 | Pharmaceutical Forms for the Release of Active Compounds - Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa. | 12-16-2010 |
20120022020 | PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS - A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan. | 01-26-2012 |
20120189698 | Pharmaceutical Dosage Forms for the Release of Active Compounds - Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa. | 07-26-2012 |
Ibon Gutierro Aduriz, Madrid ES
Patent application number | Description | Published |
---|---|---|
20130171202 | Antipsychotic Injectable Depot Composition - The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks. | 07-04-2013 |
20130177603 | Methods for the Preparation of Injectable Depot Compositions - Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days. | 07-11-2013 |
Ibon Iribarren Aristizabal, Elgoibar ES
Patent application number | Description | Published |
---|---|---|
20150078852 | MACHINE AND METHOD FOR MACHINING ENDS OF CRANKSHAFTS - The invention relates to a machine comprising a first machining module ( | 03-19-2015 |
Ibon Perez Unzurrunzaga, Pamplona ES
Patent application number | Description | Published |
---|---|---|
20110248506 | ASSEMBLY OF COMPONENTS INSIDE A LARGE WIND TURBINE - Assembly of components inside a large wind turbine, positioned between the upper section ( | 10-13-2011 |
Ibon Sedano Perez, Zamudio (bizkaia) ES
Patent application number | Description | Published |
---|---|---|
20140354105 | CONSTRUCTION ARRANGEMENT OF A PERMANENT MAGNET ROTOR FOR A GENERATOR - Construction arrangement of a permanent magnet rotor in an electric machine that comprises a plurality of notches having permanent magnets inserted axially to form the poles of the electric machine. The magnetic magnets are arranged in the notches made in the geometry of the magnetic plate constituting the mechanical structure of the rotor. The axial notches divide the geometry of the rotor stacked plate into two areas separated by a narrow magnetic strip known as the bridge, through which the dispersion magnetic flux is regulated. The dispersion magnetic flux established thereby is reduced by at least 20% because of the recess on the mentioned bridge. | 12-04-2014 |